A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

被引：4
|
作者：
Ansell, Stephen M. [1 ]
Tang, Hui
Kurtin, Paul
Koenig, Patricia
Inwards, David J. [1 ]
Shah, Keith [2 ]
Witzig, Thomas E. [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Dayton Oncol Hematol Consultants, Dayton, OH USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.1665.1665
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：664 / 665
页数：2
相关论文
共 50 条
  • [21] Growth inhibitory effect of Temsirolimus (CCI-779) alone and in combination with irradiation on HNSCC cell lines
    Niehr, F.
    Boyko-Fabian, M.
    Budach, V
    Tinhofer, I
    ONKOLOGIE, 2012, 35 : 194 - 194
  • [22] Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma
    Roccaro, A. M.
    Leduc, R.
    Nelson, M.
    Sam, A.
    Chuma, S.
    Colson, K.
    O'Connor, K.
    Ghobrial, I. M.
    Munshi, N. C.
    Schlossman, R.
    Harris, B.
    Warren, D.
    Dollard, A. M.
    Laubach, J.
    Vij, R.
    Campagnaro, E.
    Birner, A.
    Dixon-Lipscomb, V.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S86 - S86
  • [23] Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
    Samad, Nousheen
    Younes, Anas
    ONCOTARGETS AND THERAPY, 2010, 3 : 167 - 178
  • [24] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Buske, Christian
    Borchmann, Peter
    Medler, Christoph
    Witzens-Harig, Mathias
    Dreyling, Martin H.
    BLOOD, 2011, 118 (21) : 1159 - 1159
  • [25] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Bitz, Ulrich
    Lerchenmueller, Christian
    Karola, Wagner
    Medler, Christoph
    Ruckes, Christian
    Witzens-Harig, Mathias
    Huebel, Kai
    LaRosee, Paul
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [26] Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
    Hofmeister, Craig C.
    Benson, Don
    Efebera, Yvonne A.
    Farag, Sherif
    Grever, Michael R.
    BLOOD, 2009, 114 (22) : 1126 - 1126
  • [27] Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results
    Hess, Georg
    Karola, Wagner
    LaRosee, Paul
    Keller, Ulrich
    Atta, Johannes
    Witzens-Harig, Mathias
    Crombe, Anne
    Medler, Christoph
    Borchmann, Peter
    Bitz, Ulrich
    Lerchenmuller, Christian
    Theobald, Matthias
    Dreyling, Martin H.
    BLOOD, 2016, 128 (22)
  • [28] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    G Hess
    U Keller
    C W Scholz
    M Witzens-Harig
    J Atta
    C Buske
    S Kirschey
    C Ruckes
    C Medler
    C van Oordt
    W Klapper
    M Theobald
    M Dreyling
    Leukemia, 2015, 29 : 1695 - 1701
  • [29] PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Chang, Susan
    Kuhn, John
    Lamborn, Kathleen
    Robins, H. Ian
    Yung, Alfred
    Gilbert, Mark R.
    Cloughesy, Timothy
    Lieberman, Frank
    DeAngelis, Lisa
    Abrey, Lauren
    Drappatz, Jan
    Kesari, Santosh
    Dancey, Janet
    Prados, Michel D.
    NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
  • [30] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
    Hess, G.
    Keller, U.
    Scholz, C. W.
    Witzens-Harig, M.
    Atta, J.
    Buske, C.
    Kirschey, S.
    Ruckes, C.
    Medler, C.
    van Oordt, C.
    Klapper, W.
    Theobald, M.
    Dreyling, M.
    LEUKEMIA, 2015, 29 (08) : 1695 - 1701
12345